Video

What’s Next in HER2+ and Exon 19 Deletions in NSCLC?

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, recap the 2021 ASCO Annual Meeting and focus on data presented in patients with non–small cell lung cancer that is HER2 positive or harbors an exon 19 deletion.

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, recap the 2021 ASCO Annual Meeting and focus on data presented in patients with non–small cell lung cancer that is HER2 positive or harbors an exon 19 deletion.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.